JP6675688B2 - ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 - Google Patents

５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 Download PDF

Info

Publication number
JP6675688B2
JP6675688B2 JP2017555768A JP2017555768A JP6675688B2 JP 6675688 B2 JP6675688 B2 JP 6675688B2 JP 2017555768 A JP2017555768 A JP 2017555768A JP 2017555768 A JP2017555768 A JP 2017555768A JP 6675688 B2 JP6675688 B2 JP 6675688B2
Authority
JP
Japan
Prior art keywords
individual
smoking
composition
tobacco
nicotine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017555768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519251A5 (https=
JP2018519251A (ja
Inventor
アルバート エス． レン，
アルバート エス． レン，
グレアム センプル，
グレアム センプル，
シューウェン チュー，
シューウェン チュー，
カールトン アール． セージ，
カールトン アール． セージ，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド, アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018519251A publication Critical patent/JP2018519251A/ja
Publication of JP2018519251A5 publication Critical patent/JP2018519251A5/ja
Application granted granted Critical
Publication of JP6675688B2 publication Critical patent/JP6675688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017555768A 2015-04-27 2016-04-26 ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 Active JP6675688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153082P 2015-04-27 2015-04-27
US62/153,082 2015-04-27
PCT/US2016/029308 WO2016176177A1 (en) 2015-04-27 2016-04-26 5-ht2c receptor agonists and compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2018519251A JP2018519251A (ja) 2018-07-19
JP2018519251A5 JP2018519251A5 (https=) 2019-05-30
JP6675688B2 true JP6675688B2 (ja) 2020-04-01

Family

ID=55949111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555768A Active JP6675688B2 (ja) 2015-04-27 2016-04-26 ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法

Country Status (18)

Country Link
US (1) US10392390B2 (https=)
EP (1) EP3288946B1 (https=)
JP (1) JP6675688B2 (https=)
KR (1) KR102275505B1 (https=)
CN (1) CN107873030B (https=)
AU (1) AU2016255009B2 (https=)
BR (1) BR112017023088B1 (https=)
CA (1) CA3002544C (https=)
DK (1) DK3288946T3 (https=)
EA (1) EA034446B1 (https=)
ES (1) ES2757922T3 (https=)
HK (1) HK1244005B (https=)
HR (1) HRP20192044T1 (https=)
HU (1) HUE047169T2 (https=)
IL (1) IL255171A0 (https=)
MX (2) MX373319B (https=)
PT (1) PT3288946T (https=)
WO (1) WO2016176177A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
EP3746126B1 (en) 2018-01-30 2024-07-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea or simple snoring
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4635514A3 (en) * 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US12205686B2 (en) * 2020-02-27 2025-01-21 The Cleveland Clinic Foundation Identifying patients for intensive hyperglycemia management
US20250073206A1 (en) * 2021-10-29 2025-03-06 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
JP2024546484A (ja) * 2021-12-10 2024-12-24 ジーエーティーシー ヘルス コーポレーション 中毒および神経障害を治療する方法
CA3254932A1 (en) * 2022-03-10 2023-09-14 Arena Pharmaceuticals, Inc. TREATMENT METHODS
CN114965250B (zh) * 2022-05-19 2025-02-14 道生天合材料科技(上海)股份有限公司 胶粘剂储存期的预测方法
WO2023225773A1 (en) * 2022-05-23 2023-11-30 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
EP4626437A1 (en) 2022-12-02 2025-10-08 Arena Pharmaceuticals, Inc. Methods of treatment
WO2024173626A1 (en) * 2023-02-17 2024-08-22 Caamtech, Inc. 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride
CN121127458A (zh) * 2023-03-02 2025-12-12 亚历山大舒尔金研究所有限公司 苯烷胺前药
TW202529748A (zh) * 2023-10-11 2025-08-01 義大利帕多瓦大學 使用賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）及賽洛辛（ｐｓｉｌｏｃｉｎ）衍生物之治療方法
US20260048069A1 (en) 2024-07-26 2026-02-19 Arena Pharmaceuticals, Inc. Methods of treatment
WO2026043678A1 (en) 2024-08-23 2026-02-26 Arena Pharmaceuticals, Inc. Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
US20260091039A1 (en) 2024-10-01 2026-04-02 Arena Pharmaceuticals, Inc. Hydrochloric acid salt of a 5-ht2c agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642822A (en) * 1969-11-03 1972-02-15 Upjohn Co Hexahydropyrrolobenzodiazepines
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
ES2230382T3 (es) * 2000-11-03 2005-05-01 Wyeth Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
AU2002227170A1 (en) * 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TW200806321A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment or prevention of psychotic disorders
US9556200B2 (en) * 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound
SG11201501894VA (en) * 2012-09-14 2015-04-29 Abbvie Inc Tricyclic quinoline and quinoxaline derivatives
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
HUE047169T2 (hu) 2020-04-28
US10392390B2 (en) 2019-08-27
EA201792356A1 (ru) 2018-05-31
BR112017023088A2 (pt) 2018-07-10
PT3288946T (pt) 2019-11-27
IL255171A0 (en) 2017-12-31
US20180186797A1 (en) 2018-07-05
CN107873030B (zh) 2021-03-19
BR112017023088B1 (pt) 2023-10-03
MX373319B (es) 2020-06-13
MX2020005898A (es) 2020-08-13
ES2757922T3 (es) 2020-04-30
WO2016176177A1 (en) 2016-11-03
EP3288946A1 (en) 2018-03-07
JP2018519251A (ja) 2018-07-19
KR20170140317A (ko) 2017-12-20
HRP20192044T1 (hr) 2020-02-07
CN107873030A (zh) 2018-04-03
CA3002544A1 (en) 2016-11-03
EA034446B1 (ru) 2020-02-10
NZ737412A (en) 2021-06-25
KR102275505B1 (ko) 2021-07-08
AU2016255009A1 (en) 2017-12-14
AU2016255009B2 (en) 2020-10-08
CA3002544C (en) 2024-03-05
EP3288946B1 (en) 2019-08-21
HK1244005B (en) 2020-04-17
MX2017013902A (es) 2018-03-16
DK3288946T3 (da) 2019-11-25

Similar Documents

Publication Publication Date Title
JP6675688B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
JP2018519251A5 (https=)
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
HK1244005A1 (en) 5-ht2c receptor agonists and compositions and methods of use
JP6789578B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
TW201605856A (zh) ５－ＨＴｃ受體促效劑
NZ737412B2 (en) 5-ht2c receptor agonists and compositions and methods of use
NZ739883B2 (en) 5-ht2c receptor agonists and compositions and methods of use

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200228

R150 Certificate of patent or registration of utility model

Ref document number: 6675688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250